STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary
Amgen (NASDAQ:AMGN) declares a $2.25 per share dividend for Q1 2024, marking the 12th consecutive year of dividend increase. The dividend reflects the company's commitment to innovation and balance sheet improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
dividends
-
Rhea-AI Summary
Amgen (AMGN) presents new data at the 65th ASH Annual Meeting, showcasing the potential of BLINCYTO, KYPROLIS, and biosimilar eculizumab as treatment options for blood cancer patients. The company continues to advance its innovative hematology medicines, emphasizing the expanding potential of its BiTE molecule, BLINCYTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) to Present at Evercore ISI HealthCONx Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
Rhea-AI Summary
AMGN: deCODE Genetics Study Reveals 1 in 25 Carries Genotype Associated with Shortened Lifespan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) announced new data reinforcing the safety and efficacy of Repatha (evolocumab) from the FOURIER Open Label Extension (OLE) trial. The data showed no cognitive decline associated with very low levels of LDL-C. Amgen also presented new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran, focusing on cardiovascular risks associated with elevated Lp(a).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary
AMGN: Otezla Improves Disease Control in Psoriatic Arthritis Patients - Amgen's Otezla (apremilast) shows promising results in a Phase 4 study for early oligoarticular psoriatic arthritis, with twice as many patients achieving minimal disease activity compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Rhea-AI Summary
Amgen (NASDAQ:AMGN) Announces Positive Results from Phase 2 Trial of Dazodalibep for Sjögren's Treatment at ACR Convergence 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
A new study from deCODE genetics, a subsidiary of Amgen, provides insights into clonal hematopoiesis. The study used whole-genome sequence data from over 176,000 people and found that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old. Smoking was found to accelerate the development of clonal hematopoiesis. The study also identified mutations that drive clonal expansion and 25 inherited sequence variants that predispose individuals to develop clonal hematopoiesis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary
Amgen announces new data for KRYSTEXXA showing a decrease in blood pressure during treatment of adults with chronic gout refractory to oral urate-lowering treatment. The data will be presented at the American Society of Nephrology Kidney Week.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
Rhea-AI Summary
Amgen announces the presentation of new scientific and clinical research in rheumatology at the American College of Rheumatology Convergence 2023. The data includes studies on Sjögren's Syndrome, uncontrolled gout, severe active ANCA-associated vasculitis, and psoriatic arthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $283.61 as of November 15, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 150.6B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

150.64B
536.44M
0.25%
81.23%
1.74%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS